

Mereo Biopharma Group Plc (mph.1)

it is also evaluating sativex in a phase 3 program for the treatment of cancer pain, and anticipates that top-line results from two phase 3 trials will be available in 2014.

biopharma group bangalore

biopharma group egypt

mereo biopharma group plc (mph.1)

mereo biopharma group plc bloomberg

biopharma group india

biopharma group san francisco